Badrajee Piyarathna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Badrajee Piyarathna has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Albert R. Klekers
Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1473, Houston, TX 77030
9 shared publications - Antrix Jain
Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX
9 shared publications - Brittany E. Jewell
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
9 shared publications - Caroline Fidalgo Ribeiro
Weill Cornell Medical College, New York, NY, USA
9 shared publications - Cristian Coarfa
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
9 shared publications - Daniel E. Frigo
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
9 shared publications
Latest Publications
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Dataset of Phosphoproteomics Analyses of Patient Samples
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Dataset of Phosphoproteomics Analyses of Patient Samples
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Dataset of Phosphoproteomics Analyses of Patient Samples
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Dataset of Phosphoproteomics Analyses of Patient Samples
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
IP/MS summary table describing the ATGL interactome in C4-2 cells.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
IP/MS summary table describing the ATGL interactome in C4-2 cells.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Tables 1-8 to accompany the main text and, in particular, the materials and methods.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Tables 1-8 to accompany the main text and, in particular, the materials and methods.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
IP/MS summary table describing the ATGL interactome in C4-2 cells.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
IP/MS summary table describing the ATGL interactome in C4-2 cells.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
28 supplementary figures supporting the main text and main figures.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
28 supplementary figures supporting the main text and main figures.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
28 supplementary figures supporting the main text and main figures.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
28 supplementary figures supporting the main text and main figures.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Tables 1-8 to accompany the main text and, in particular, the materials and methods.
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Supplementary Tables 1-8 to accompany the main text and, in particular, the materials and methods.
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (5) , 703-724
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Lipid metabolism plays a central role in prostate cancer. To date, the major focus has centered on de novo lipogenesis and lipid uptake in prostate cancer, but inhibitors of these processes have not benefited patients. A better understanding of how cancer cells access lipids once they are created or taken up and stored could uncover more effective strategies to perturb lipid metabolism and treat patients. Here, we identified that expression of adipose triglyceride lipase (ATGL), an enzyme that controls lipid droplet homeostasis and a previously suspected tumor suppressor, correlates with worse overall survival in men with advanced, castration-resistant prostate cancer (CRPC). Molecular, genetic, or pharmacologic inhibition of ATGL impaired human and murine prostate cancer growth in vivo and in cell culture or organoids under conditions mimicking the tumor microenvironment. Mass spectrometry imaging demonstrated that ATGL profoundly regulates lipid metabolism in vivo, remodeling membrane composition. ATGL inhibition induced metabolic plasticity, causing a glycolytic shift that could be exploited therapeutically by cotargeting both metabolic pathways. Patient-derived phosphoproteomics identified ATGL serine 404 as a target of CAMKK2–AMPK signaling in CRPC cells. Mutation of serine 404 did not alter the lipolytic activity of ATGL but did decrease CRPC growth, migration, and invasion, indicating that noncanonical ATGL activity also contributes to disease progression. Unbiased immunoprecipitation/mass spectrometry suggested that mutation of serine 404 not only disrupts existing ATGL protein interactions but also leads to new protein–protein interactions. Together, these data nominate ATGL as a therapeutic target for CRPC and provide insights for future drug development and combination therapies. Significance: ATGL promotes prostate cancer metabolic plasticity and progression through both lipase-dependent and lipase-independent activity, informing strategies to target ATGL and lipid metabolism for cancer treatment.
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (5) , 703-724
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Lipid metabolism plays a central role in prostate cancer. To date, the major focus has centered on de novo lipogenesis and lipid uptake in prostate cancer, but inhibitors of these processes have not benefited patients. A better understanding of how cancer cells access lipids once they are created or taken up and stored could uncover more effective strategies to perturb lipid metabolism and treat patients. Here, we identified that expression of adipose triglyceride lipase (ATGL), an enzyme that controls lipid droplet homeostasis and a previously suspected tumor suppressor, correlates with worse overall survival in men with advanced, castration-resistant prostate cancer (CRPC). Molecular, genetic, or pharmacologic inhibition of ATGL impaired human and murine prostate cancer growth in vivo and in cell culture or organoids under conditions mimicking the tumor microenvironment. Mass spectrometry imaging demonstrated that ATGL profoundly regulates lipid metabolism in vivo, remodeling membrane composition. ATGL inhibition induced metabolic plasticity, causing a glycolytic shift that could be exploited therapeutically by cotargeting both metabolic pathways. Patient-derived phosphoproteomics identified ATGL serine 404 as a target of CAMKK2–AMPK signaling in CRPC cells. Mutation of serine 404 did not alter the lipolytic activity of ATGL but did decrease CRPC growth, migration, and invasion, indicating that noncanonical ATGL activity also contributes to disease progression. Unbiased immunoprecipitation/mass spectrometry suggested that mutation of serine 404 not only disrupts existing ATGL protein interactions but also leads to new protein–protein interactions. Together, these data nominate ATGL as a therapeutic target for CRPC and provide insights for future drug development and combination therapies. Significance: ATGL promotes prostate cancer metabolic plasticity and progression through both lipase-dependent and lipase-independent activity, informing strategies to target ATGL and lipid metabolism for cancer treatment.